secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2022-07-26T23:59:59+00:00
Accession:  0001157523-22-000904
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva Q2 revenue $3.8B, non-GAAP EPS $0.68; reaches $4.25B opioids settlement in principle
--------------------------------------------------------------------------------

- Revenue $3.8B (-3% YoY, +1% local currency); GAAP loss $0.21, non-GAAP EPS $0.68 vs $0.59 prior year
- Agreed in principle to nationwide opioids settlement: up to $4.25B + $100M for tribes over 13 years, includes Narcan supply
- Revised 2022 revenue guidance to $15.0-$15.6B from $15.4-$16.0B due to FX; reaffirmed adjusted EBITDA, EPS, FCF
- COPAXONE outlook lowered to ~$700M from ~$750M; non-GAAP tax rate outlook cut to 13%-14% from 18%-19%
- Cash flow from ops $123M, free cash flow $301M; goodwill impairment and legal settlements drove GAAP loss

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000115752322000904/0001157523-22-000904-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000115752322000904/a52792738.htm
  HTML page:      https://secwatch.observer/filing/0001157523-22-000904

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer